Grufity logo
Grufity logo
INKT

INKT - MiNK Therapeutics, Inc. Stock Price, Fair Value and News

$11.82-0.71 (-5.67%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

Price Targets

INKT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

INKT Price Action

Last 7 days

12.3%

Last 30 days

18.8%

Last 90 days

33.0%

Trailing 12 Months

75.6%

INKT RSI Chart

INKT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

INKT Valuation

Market Cap

60.1M

Price/Earnings (Trailing)

-4.82

Price/Sales (Trailing)

10.08

Price/Free Cashflow

-9.52

INKT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

INKT Fundamentals

INKT Revenue

Revenue (TTM)

5.8M

INKT Earnings

Earnings (TTM)

-12.5M

Earnings Growth (Yr)

0.88%

Earnings Growth (Qtr)

-5.39%

INKT Profitability

Return on Equity

98.3%

Return on Assets

-120.17%

Free Cashflow Yield

-10.51%

INKT Investor Care

Shares Dilution (1Y)

21.01%

Diluted EPS (TTM)

-2.81

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2024---5.8M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About MiNK Therapeutics, Inc.

INKT
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It's product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
 CEO
 WEBSITEhttps://minktherapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES37

MiNK Therapeutics, Inc. Frequently Asked Questions

INKT is the stock ticker symbol of MiNK Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of MiNK Therapeutics, Inc. is 60.12 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, INKT's PE ratio (Price to Earnings) is -4.82 and Price to Sales (PS) ratio is 10.08. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INKT PE ratio will change depending on the future growth rate expectations of investors.